Large Core at Presentation Does Not Essentially Translate Into Poor Outcomes, May Be Amenable to Treatment in Select Patients
Kaustubh Limaye, MD
Gautheron V, Xie Y, Tisserand M, Raoult H, Soize S, Naggara O, et al. Outcome After Reperfusion Therapies in Patients With Large Baseline Diffusion-Weighted Imaging Stroke Lesions: A THRACE Trial (Mechanical Thrombectomy After Intravenous Alteplase Versus Alteplase Alone After Stroke) Subgroup Analysis. Stroke. 2018
The treatment landscape of acute ischemic stroke secondary to large vessel occlusion changed significantly in 2015 with the publication of 5 clinical trials that compared intravenous alteplase (IV t-pA) with IV t-pA and intra-arterial therapy (IAT). These clinical trials showed unequivocal benefit in reducing morbidity with the ESCAPE trial even showing mortality benefit. A similar trial conducted at 26 centers in France, THRACE (mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke) randomized 414 acute stroke patients with large vessel occlusion in either arm (IV t-PA vs IV tPA + IAT). 42 % of patients (IV tPA alone) vs. 53% (IV tPA +IAT) achieved functional independence [OR-1.55,95%CI 1.05-2.30; p-0.028], supporting data from the previous clinical trials. As this study was designed before the results of the IMS-III were published, it included patients treated within 4 hours of symptom onset. Other inclusion criteria were age 18-80 years, NIHSS 10-25, both anterior and posterior circulation and initiation of IAT within 5 hours.